Журнал инфектологии (Jul 2018)
Comparative clinical and economic evaluation of two alternative antiviral therapy regimens for influenza patients
Abstract
In the Russian Federation, the number of new cases of influenzaand SARS each year reaches 30 million people, and the annual total economic damage is estimated at 40 billion rubles, accounting for about 80% of the damage from all infectious diseases. Today, one of the main priorities of confronting the consequences of the annual epidemics of influenza is the development and introduction into clinical practice of new drugs with proven effectiveness and safety, the use of which is economically feasible.Objective. Conduct a clinical and economic analysis of two alternative regimens for treating influenza patients using the modern drug Triasavirin® and the known Tamiflu® neuraminidase inhibitor.Materials and methods. The study included 127 patients with a laboratory confirmed diagnosis of «influenza». All patients were divided into two groups. The main group consisted of 82 patients who received Triazavirin® 1 capsule (250 mg) 3 times a day for 5 days. The comparison group consisted of 45 patients who received Tamiflu® 1 capsule (75 mg) 2 times a day for 5 days. To conduct a clinical and economic evaluation of two alternative treatment regimens, cost-effectiveness factors were calculated, such as the ratio of the cost of therapy to the indicator of its effectiveness. The analyzed events were: (1) recovery by the 5th day from the start of treatment; (2) temperature normalization by the 5th day from the start of treatment; (3) no symptoms of intoxication (headache, myalgia, pain / rei in the eyeballs) by the 5th day from the start of treatment; (4) absence of catarrhal manifestations (pain / sore throat, cough) to the 10th day from the beginning of treatment.Results. The use of the drug Triazavirin® for treatment of influenza patients in comparison with the inhibitor of neuraminidase with Tamiflu® is economically viable, both with respect to the timing of recovery (cost-effectiveness ratio: 935,57 rubles / unit vs 1859,39 rubles / unit) and normalization of temperature body (cost- effectiveness ratio: 869,53 rubles / unit vs. 2014,33 rubles / unit), and with respect to the duration of intoxication (cost-effectiveness ratio: 859,42 rubles / unit vs. 1473,90 rub ./unit) and catarrhal (coefficient of expenditure e ciency: 869,53 rubles / unit against 1611,47 rubles / unit) syndromes.Conclusion. Triazavirin® is a new effective antiviral agent for the treatment of influenza. The use of Triazavirin® in the treatment of patients with influenza is economically viable, due to significant budget savings both in terms of the cost of treatment, and the reduction in concomitant therapy and the reduction in the period of temporary disability of working patients.
Keywords
